This multicenter, double-blind, randomized controlled trial evaluates the efficacy and safety of acupoint catgut embedding (ACE) in patients with mild psoriasis and overweight. Participants aged ≥ 18 years with mild plaque psoriasis (PASI < 3, BSA < 3%) and BMI ≥ 24 kg/m² will be randomized 1:1 to real ACE at 14 acupoints or sham procedure. Interventions are delivered every 2 weeks for 8 weeks. Primary endpoints are changes in PASI score and BMI from baseline to week 8. Secondary outcomes include Dermatology Life Quality Index (DLQI), waist circumference, lipid profile, and systemic inflammatory markers. Safety is monitored by recording adverse events and laboratory tests, with patients being followed up to week 32 to assess long-term efficacy. The study will provide evidence for the dual action of ACE on psoriatic lesions and metabolic disorders. Registration: ITMCTR2025002460.